Cost-effectiveness of captopril therapy after myocardial infarction
| Autor: | Joel Tsevat, Thomas H. Lee, Lee Goldman, Karen M. Kuntz, Daniella Duke, Marc A. Pfeffer, Jane Soukup, Gervasio A. Lamas |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
Value of Life medicine.medical_specialty Captopril Cost effectiveness Cost-Benefit Analysis Myocardial Infarction Angiotensin-Converting Enzyme Inhibitors Drug Costs Decision Support Techniques law.invention Randomized controlled trial law Internal medicine Humans Medicine Myocardial infarction Hospitals Teaching Aged Aged 80 and over Ejection fraction business.industry Stroke Volume Stroke volume Middle Aged medicine.disease Markov Chains Quality-adjusted life year Surgery Clinical trial Cardiology Female Quality-Adjusted Life Years Cardiology and Cardiovascular Medicine business Boston medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 26:914-919 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/0735-1097(95)00284-1 |
| Popis: | Objectives. This study sought to assess the cost-effectiveness of captopril therapy for survivors of myocardial infarction. Background. The recent randomized, controlled Survival and Ventricular Enlargement (SAVE) trial showed that captopril therapy improves survival in survivors of myocardial infarction with an ejection fraction ≤40%. The present ancillary study was designed to determine how the costs required to achieve this increase in survival compared with those of other medical interventions. Methods. We developed a decision-analytic model to assess the cost-effectiveness of captopril therapy in 50- to 80-year old survivors of myocardial infarction with an ejection fraction ≤40%. Data on costs, utilities (health-related quality of life weights) and 4-year survival were obtained directly from the SAVE trial, and long-term survival was estimated using a Markov model. In one set of analyses, we assumed that the survival benefit associated with captopril therapy would persist beyond 4 years (persistent-benefit analyses), whereas in another set we assumed that captopril therapy incurred costs but no survival benefit beyond 4 years (limited-benefit analyses). Results. In the limited-benefit analyses, the incremental cost-effectiveness of captopril therapy ranged from $3,600/quality-adjusted life-year for 80-year old patients to $60,800/quality-adjusted life-year for 50-year old patients. In the persistent-benefit analyses, incremental cost-effectiveness ratios ranged from $3,700 to $10,400/quality-adjusted life-year, depending on age. The outcome was generally not sensitive to changes in estimates of variables when they were varied individually over wide ranges. In a “worst-case” analysis, incremental cost-effectiveness ratios for captopril therapy remained favorable ($8,700 to $29,200/ quality-adjusted life-year) for 60- to 80-year old patients but were higher ($217,600/quality-adjusted life-year) for 50-year old patients. Conclusions. We conclude that the cost-effectiveness of captopril therapy for 50- to 80-year old survivors of myocardial infarction with a low ejection fraction compares favorably with other interventions for survivors of myocardial infarction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|